Related references
Note: Only part of the references are listed.Clinical outcome with bevacizumab in patients with recurrent high-grade glioma treated outside clinical trials
Silvia Hofer et al.
ACTA ONCOLOGICA (2011)
Aspirin, Warfarin, or Enoxaparin Thromboprophylaxis in Patients With Multiple Myeloma Treated With Thalidomide: A Phase III, Open-Label, Randomized Trial
Antonio Palumbo et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Combination of 6-thioguanine, capecitabine, and celecoxib with temozolomide or lomustine for recurrent high-grade glioma
Tobias Walbert et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee et al.
NEURO-ONCOLOGY (2010)
Bevacizumab for Recurrent Alkylator-Refractory Anaplastic Oligodendroglioma
Marc C. Chamberlain et al.
CANCER (2009)
Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas
Nicholas Butowski et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Experience with irinotecan for the treatment of malignant glioma
James J. Vredenburgh et al.
NEURO-ONCOLOGY (2009)
Bevacizumab and irinotecan for recurrent oligodendroglial tumors
S. Taillibert et al.
NEUROLOGY (2009)
FDA Drug Approval Summary: Bevacizumab (Avastin (R)) as Treatment of Recurrent Glioblastoma Multiforme
Martin H. Cohen et al.
ONCOLOGIST (2009)
Salvage chemotherapy with CPT-11 for recurrent temozolomide-refractory anaplastic astrocytoma
Marc C. Chamberlain et al.
CANCER (2008)
Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas
Annick Desjardins et al.
CLINICAL CANCER RESEARCH (2008)
CPT-11 for recurrent temozolomide-refractory 1p19q co-deleted anaplastic oligodendroglioma
Marc C. Chamberlain et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme
Vinay K. Puduvalli et al.
NEURO-ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults
Santosh Kesari et al.
NEURO-ONCOLOGY (2007)
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas
Annick Desjardins et al.
JOURNAL OF NEURO-ONCOLOGY (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Prospective evaluation of low-dose warfarin for prevention of thalidomide associated venous thromboembolism
Kena C. Miller et al.
LEUKEMIA & LYMPHOMA (2006)
Prognostic stratification of patients with anaplastic gliomas according to genetic profile
Caroline Dehais et al.
CANCER (2006)
Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: A prospective GICNO study
Alba A. Brandes et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma
DA Reardon et al.
CANCER (2005)
Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma
DA Reardon et al.
NEURO-ONCOLOGY (2004)
Phase II trial of thalidomide and carmustine for patients with recurrent high-grade gliomas
HA Fine et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen
TF Cloughesy et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2002)
Thalidomide as an anti-angiogenic agent in relapsed gliomas
SC Short et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Antiangiogenesis - therapeutic strategies and clinical implications for brain tumors
VK Puduvalli et al.
JOURNAL OF NEURO-ONCOLOGY (2000)
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
HA Fine et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
